trending Market Intelligence /marketintelligence/en/news-insights/trending/sIq0XvvLGwdDmkDCbdd-0A2 content esgSubNav
In This List

Alterity drug wins EU orphan-drug tag for Parkinson's-like disorder

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Alterity drug wins EU orphan-drug tag for Parkinson's-like disorder

Alterity Therapeutics Ltd. said the European Commission granted an orphan-drug designation to PBT434 for treating a neurodegenerative disorder called multiple system atrophy.

Multiple system atrophy, or MSA, is a rare, degenerative neurological disorder that affects the body's involuntary functions, including blood pressure, breathing, bladder function and muscle control. It is a form of atypical Parkinson's, where patients present symptoms similar to Parkinson's but do not respond to therapy.

Under the designation, the Australian biotechnology company will have market exclusivity in the EU for 10 years, subject to regulatory approval. Additionally, Alterity will be eligible for benefits such as assistance in developing clinical trials, reduced fees and access to research grants.

The European Medicines Agency's Committee for Orphan Medicinal Products recommended PBT434 for the designation in November 2019.

The U.S. Food and Drug Administration granted orphan-drug designation to PBT434 to treat MSA.